Novel principles for osteoporosis treatment

Background

Osteoporosis: The silent killer
- Osteoporosis is a highly prevalent age-related disease
- One in 2 women and 1 in 5 men over the age of 50 years will suffer from an osteoporotic fracture and thereby be at increased risk of complications and death

Aim

To develop a highly specific co-agonist which can inhibit bone resorption and stimulate bone formation simultaneously.

Value proposition/USP
- Dual receptor agonist
- Small peptide backbone
- High potency
- High specificity

Business Opportunity/Objective/commercial perspectives
Worldwide, it is estimated that there are around 9 million osteoporotic fractures per year. In the United States, the direct costs of osteoporotic fractures are estimated at around $18 billion annually and in Europe the corresponding figure is around €36 billion. These costs are set to increase twofold or more by 2050. The technology is available for licensing and research collaborations.

Technology description
Based on published and unpublished data of ligand binding-modes to the GIP and GLP-2 receptors, we were able to develop GIPR/GLP-2R co-agonists of which the best two had potencies of maximum 6-fold difference compared to the native hormones on these two receptors.

Development phase/current state
At present we already succeeded in designing single molecules, that are capable of activating both the GIPR and GLP-2R with a very high potency. Ongoing work involves improvement of receptor affinity and prolonged T½.

The inventors
Maria Nordskov Gabe
Lærke Smidt Gasbjerg
Prof. Mette Marie Rosenkilde
Prof. Jens Juul Holst
Ass. Prof. Bolette Hartmann

Contact information
Peter Stein Nielsen
Commercial Officer
peter.nielsen@adm.ku.dk
+45 2164 7447

Intellectual property rights: Danish priority patent application filed on October 12, 2016